AU2001284576A1 - The synergetic effects of hgf and antibacterial treatment - Google Patents

The synergetic effects of hgf and antibacterial treatment

Info

Publication number
AU2001284576A1
AU2001284576A1 AU2001284576A AU8457601A AU2001284576A1 AU 2001284576 A1 AU2001284576 A1 AU 2001284576A1 AU 2001284576 A AU2001284576 A AU 2001284576A AU 8457601 A AU8457601 A AU 8457601A AU 2001284576 A1 AU2001284576 A1 AU 2001284576A1
Authority
AU
Australia
Prior art keywords
hgf
antibacterial treatment
ongoing
synergetic effects
septicaemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001284576A
Inventor
Fariba Nayeri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0003038A external-priority patent/SE0003038L/en
Priority claimed from SE0101823A external-priority patent/SE0101823D0/en
Application filed by Individual filed Critical Individual
Publication of AU2001284576A1 publication Critical patent/AU2001284576A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention relates to a kit for determining HGF in excrement from a patient to determine an ongoing infection selected from the group consisting of: pneumonia, pyelonephritis, infectious gastroenteritis, septicaemia, and acute meningitis, and/or to determine ongoing treatment of such infection, comprising a HGF determinant. The invention also relates to in vitro methods for diagnosing ongoing infections selected from the group consisting of: pneumonia, pyelonephritis, infectious gastroenteritis, septicaemia, and acute meningitis, wherein the excremental presence of HGF is determined.
AU2001284576A 2000-08-28 2001-08-28 The synergetic effects of hgf and antibacterial treatment Abandoned AU2001284576A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE0003038 2000-08-28
SE0003038A SE0003038L (en) 2000-08-28 2000-08-28 Synergistic effects of HGF and antibacterial treatment
SE0101823 2001-05-21
SE0101823A SE0101823D0 (en) 2001-05-21 2001-05-21 Analysis of excrement with regard to hepatocyte growth factor
PCT/SE2001/001831 WO2002017964A1 (en) 2000-08-28 2001-08-28 The synergetic effects of hgf and antibacterial treatment

Publications (1)

Publication Number Publication Date
AU2001284576A1 true AU2001284576A1 (en) 2002-03-13

Family

ID=26655219

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001284576A Abandoned AU2001284576A1 (en) 2000-08-28 2001-08-28 The synergetic effects of hgf and antibacterial treatment

Country Status (7)

Country Link
US (2) US7601365B2 (en)
EP (3) EP1840575A1 (en)
AT (1) ATE375168T1 (en)
AU (1) AU2001284576A1 (en)
DE (1) DE60130906T2 (en)
ES (1) ES2295198T3 (en)
WO (1) WO2002017964A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037365A1 (en) * 2001-11-01 2003-05-08 The Johns Hopkins University Methods and compositions for treating vascular leak using hepatocyte growth factor
JP4728807B2 (en) * 2003-09-03 2011-07-20 敏一 中村 Skin ulcer preventive and healing agent containing human recombinant HGF
ES2321105T3 (en) * 2003-09-29 2009-06-02 Peas Institut Ab QUICK DETERMINATION OF DIFFERENT FORMS OF THE HEPATOCITE GROWTH FACTOR (HGF) IN BODY FLUIDS.
EP1810037B1 (en) 2004-10-20 2010-07-21 PEAS Institut AB Assessment of biological activity of hepatocyte growth factor (hgf)
EP1957102B1 (en) * 2005-11-16 2012-01-18 Fariba Nayeri Methods for inhibiting carcinogenesis and/or metastasis in an individual with endogenous c-met ligands and inhibitors
WO2011028173A1 (en) * 2009-09-05 2011-03-10 Fariba Nayeri Method of treatment of a patient suffering from an infection or injuries caused or complicated by infection
SE536400C2 (en) 2012-02-22 2013-10-08 Peas Inst Ab New method for rapid detection of hepatocyte growth factor in biological fluids
RU2597780C1 (en) * 2015-05-21 2016-09-20 федеральное государственное бюджетное образовательное учреждение высшего образования "Тверской государственный медицинский университет" Министерства здравоохранения Российской Федерации Method for differential diagnosis of technique for salmonella gastroenteritis and alcohol gastroenteritis
RU2597781C1 (en) * 2015-05-21 2016-09-20 федеральное государственное бюджетное образовательное учреждение высшего образования "Тверской государственный медицинский университет" Министерства здравоохранения Российской Федерации Method for differential diagnosis of salmonella gastroenteritis and alcohol gastroenteritis
RU2716713C1 (en) * 2019-08-01 2020-03-16 Федеральное государственное бюджетное учреждение науки Оренбургский федеральный исследовательский центр Уральского отделения Российской академии наук Diagnostic technique for acute pyelonephritis stage

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US176347A (en) * 1876-04-18 Improvement in filling packages with comb-honey
JP2564486B2 (en) * 1986-07-14 1996-12-18 修治 橋本 Hepatocyte growth factor
US5648273A (en) * 1989-12-27 1997-07-15 The United States Of America, As Represented By The Department Of Health And Human Services Hepatic growth factor receptor is the MET proto-oncogene
JP2750372B2 (en) 1990-06-19 1998-05-13 敏一 中村 Wise disease treatment
JP3200609B2 (en) * 1990-12-28 2001-08-20 敏一 中村 Epithelial cell growth promoter
JPH083195A (en) 1991-10-04 1996-01-09 Toshiichi Nakamura Tissue injury healing factor
JP3394982B2 (en) 1991-11-07 2003-04-07 敏一 中村 Side effects inhibitor for cancer therapy
WO1994004175A1 (en) 1992-08-24 1994-03-03 Toshikazu Nakamura Hgf production promoter
JP3680114B2 (en) 1993-09-17 2005-08-10 敏一 中村 Cranial nerve disorder treatment
JP3962097B2 (en) * 1994-03-18 2007-08-22 敏一 中村 Relief of side effects caused by immunosuppressants
JP3818322B2 (en) 1994-04-28 2006-09-06 敏一 中村 Collagen degradation promoter
JP3477832B2 (en) * 1994-07-22 2003-12-10 三菱化学株式会社 Liver disease detection method
US5656443A (en) * 1994-07-29 1997-08-12 Long Island Jewish Medical Center Method of diagnosing bladder cancer
JP3737532B2 (en) 1994-08-19 2006-01-18 敏一 中村 Cartilage disorder treatment
US6756358B2 (en) * 1994-08-19 2004-06-29 Sumitomo Pharmaceuticals Co., Ltd. Therapeutic agent for cartilaginous diseases
ATE257844T1 (en) * 1995-03-10 2004-01-15 Nakamura Toshikazu HUMAN GROWTH FACTOR (HGF) ALTERED BY POLYETHYLENE GLYCOL
JPH08268907A (en) * 1995-03-31 1996-10-15 Sunstar Inc Promotor for regenerating periodontal tissue
CA2224253A1 (en) * 1995-06-09 1996-12-27 Martin J. Macphee Chitin hydrogels, methods of their production and use
ES2240999T3 (en) 1995-08-29 2005-10-16 Anges Mg, Inc. MEDICINAL CONTAINING A GENE OF HGF.
WO1997009997A1 (en) * 1995-09-12 1997-03-20 Genentech, Inc. Cystic fibrosis therapy
JP3832674B2 (en) 1995-10-24 2006-10-11 敏一 中村 Anticancer drug
US5827673A (en) * 1996-08-13 1998-10-27 Akira Matsumori Method of detecting myocardial infarction
JP4463885B2 (en) 1996-12-05 2010-05-19 敏一 中村 Fulminant hepatitis disease treatment
WO1998041227A1 (en) 1997-03-15 1998-09-24 Sumitomo Pharmaceuticals Co., Ltd. Hgf for treating acute renal failure
CA2218145C (en) * 1997-04-14 2008-01-08 Toshikazu Nakamura Method of treating dilated cardiomyopathy
DK1074264T3 (en) 1998-04-28 2008-11-24 Toshikazu Nakamura Inhibitors of neovascularization
EP1242451A2 (en) * 1999-12-15 2002-09-25 EntreMed, Inc. Compositions and methods for inhibiting endothelial cell proliferation
US20030176347A1 (en) 2003-05-14 2003-09-18 Toshikazu Nakamura Remedies for amyotrophic lateral sclerosis
JP5442173B2 (en) 2000-09-14 2014-03-12 敏一 中村 A therapeutic agent for amyotrophic lateral sclerosis

Also Published As

Publication number Publication date
US7601365B2 (en) 2009-10-13
WO2002017964A1 (en) 2002-03-07
ATE375168T1 (en) 2007-10-15
US20040042968A1 (en) 2004-03-04
EP1320384B1 (en) 2007-10-10
US20100160223A1 (en) 2010-06-24
ES2295198T3 (en) 2008-04-16
EP1840575A1 (en) 2007-10-03
EP1867996A1 (en) 2007-12-19
DE60130906D1 (en) 2007-11-22
DE60130906T2 (en) 2008-07-17
EP1320384A1 (en) 2003-06-25

Similar Documents

Publication Publication Date Title
DE60113851D1 (en) BAKTERIOPHAGE WITH WIDE HOSTEL
IS6448A (en) Bacterial properties of 3-amonoquinazole-2.4dione
EA200400536A1 (en) Macrolides
ATE327231T1 (en) QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS
AU2001284576A1 (en) The synergetic effects of hgf and antibacterial treatment
CY2011012I2 (en) INHALED AZTREONAME FOR THE TREATMENT AND PREVENTION OF BACTERIAL PULMONARY INFECTIONS
TNSN03121A1 (en) Formes cristallines d'azithromycine
DE60123276D1 (en) PIPERAZINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS
HUP0400719A2 (en) Compounds and methods for treatment and diagnosis of chlamydial infection
BRPI0007481B8 (en) formulation containing a strain of bifidobacterium and its use
DK1312635T3 (en) Dental implants with antibacterial properties
BR0112750A (en) Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
NO976119D0 (en) OMP26 antigen from Haemophilus influenzae
EP1037650A4 (en) Methods and compositions for the treatment and prevention of staphylococcus aureus infections
ES2191075T3 (en) 8-ARILALQUIL- AND 8-ARILHETEROALQUIL-5,11-DIHIDRO-6H-DIPIRIDO- (3,2-B: 2 ', 3'-E) (1,4) DIAZEPINS AND THEIR USE IN THE PREVENTION OR TREATMENT OF INFECTIONS FOR HIV.
MA28613B1 (en) ANTIBACTERIAL AMIDE MACROCYCLES
IL161512A0 (en) Low concentration of peroxide for treating or preventing vaginal infections
SE9201930D0 (en) GASTRIC ANTIBACTERIAL TREATMENT
EP0387802A3 (en) 5-substituted-1,4-dihydro-4-oxonaphthyridine-3-carboxylate antibacterial agents
AUPQ761200A0 (en) Compositions and methods for treatment of mucosal infections
NO20010140L (en) Chemotaxin-inhibiting protein of Staphylococcus (CHIPS) and its use
FR2807764B1 (en) MUTANTS OF LACTIC BACTERIA OVERPRODUCING EXOPOLYSACCHARIDES
Hauer et al. Nosocomial Infections in Germany(NIDEP)- Microbiological diagnosis, antimicrobial prophylaxis and therapy.
AU2001265876A1 (en) Novel use of pulmonary surfactant for the prophylaxis or early treatment of acute pulmonary diseases
Fari Bacterial examination of urethritis.